{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:20:44Z","timestamp":1793496044664,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 1961 the use of levodopa was introduced into the treatment of Parkinson\u2019s disease (PD). Since bradykinesia seems to reflect the death of dopaminergic nigrostriatal neurons, this observation makes sense. To date, levodopa in combination with a decarboxylase inhibitor is the safest and most efficacious oral treatment in PD. Over the last decades, motor fluctuations, the most important roblem associated with levodopa and due to its short plasma half life have been improved by the addition of MAOB-, COMT-inhibitors and dopamine agonists. Long-acting levodopa formulations are available to keep wearing-off low and to allow the use of 2\u20133 levodopa tablets per day. Rescue medication, such as oral soluble levodopa\/carbidopa or sublingual apomorphine is available as is subcutaneously applied levodopa\/carbidopa, a new tool in advice-guided therapy to come near to physiological continuous dopamine receptor stimulation and in this way allow persistent motor control. Most subtances used in PD treatment function via the dopaminergic system. One exception is amantadine, which shows anti-glutamatergic function. At present, modern treatment of PD is a dopamine replacement therapy and probably this will stay that way for a long time to come.<\/jats:p>","DOI":"10.1007\/s00702-026-03205-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:52:14Z","timestamp":1781790734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Why dopamine replacement therapy will stay as a cornerstone in the treatment of Parkinson disease: a personal opinion"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-1429","authenticated-orcid":false,"given":"Heinz","family":"Reichmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"1","key":"3205_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0022-510x(71)90256-5","volume":"12","author":"O Abramsky","year":"1971","unstructured":"Abramsky O, Lavy S, Carmon A (1971) A test for objective evaluation of motor performance in patients receiving L-dopa for Parkinson\u2019s disease. J Neurol Sci 12(1):105\u2013108. https:\/\/doi.org\/10.1016\/0022-510x(71)90256-5","journal-title":"J Neurol Sci"},{"issue":"6","key":"3205_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous folslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12(6):1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"3205_CR3","first-page":"247","volume-title":"Monoamines et syst\u00e8me nerveux central","author":"A Barbeau","year":"1962","unstructured":"Barbeau A, Sourkes TL, Murphy GF (1962) Les catholoamines dans la maladie de Parkinson. In: De Ajuriaguerra (ed) Monoamines et syst\u00e8me nerveux central. Masson, Paris, pp 247\u2013262"},{"issue":"8639","key":"3205_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/s0140-6736(89)92183-1","volume":"1","author":"R Barker","year":"1989","unstructured":"Barker R, Duncan J, Lees A (1989) Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in Parkinsonian syndromes. Lancet 1(8639):675. https:\/\/doi.org\/10.1016\/s0140-6736(89)92183-1","journal-title":"Lancet"},{"key":"3205_CR5","first-page":"787","volume":"73","author":"Q Birkmayer","year":"1961","unstructured":"Birkmayer Q, Hornykiewicz O (1961) Der L-3,4-dioxyphenylalanin (=\u2009DOPA)-effekt bei der Parkinson-Akinesie. Wien Klein Wschr 73:787\u2013788","journal-title":"Wien Klein Wschr"},{"key":"3205_CR6","first-page":"29","volume":"210","author":"W Birkmayer","year":"1967","unstructured":"Birkmayer W, Mentasi M (1967) Weitere experimentelle Untersuchungen \u00fcber den Katecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Chorea-Syndrom). Arch Psych Ges Neurol 210:29\u201335","journal-title":"Arch Psych Ges Neurol"},{"issue":"10","key":"3205_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961.","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P et al (2014) Twoi-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord 29(10):1273\u20131280. https:\/\/doi.org\/10.1002\/mds.25961","journal-title":"Mov Disord"},{"issue":"Suppl3","key":"3205_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-002-1301-4","volume":"249","author":"H Braak","year":"2002","unstructured":"Braak H, Del Tredici K, Bratzke H et al (2002) Staging of the intracerebral inclusion body pathology associated with the idiopathic Parkinson\u2019s disease. J Neurol 249(Suppl3):1\u20135","journal-title":"J Neurol"},{"key":"3205_CR9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/jnnp.45.12.1161","volume":"45","author":"Y DeSmet","year":"1982","unstructured":"DeSmet Y, Ruberg M, Serdaru M et al (1982) Confusion, dementia and anticholinergics in Parkinson\u2019s disease. J Neurol Neurosurg Psych 45:1161\u20131164","journal-title":"J Neurol Neurosurg Psych"},{"issue":"2","key":"3205_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/mds.29685","volume":"39","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Hauser RA, Dhall R et al (2024a) Safety and efficacy of IPX203 in Parkinson\u2019s disease: the RISE-PD open\u2013label extension study. Mov Disord 39(2):428\u2013432. https:\/\/doi.org\/10.1002\/mds.29685","journal-title":"Mov Disord"},{"issue":"5","key":"3205_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","volume":"23","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Stocchi F, Pahwa R et al (2024b) Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson\u2019s disease with motor fluctuations (boNDless): a phase3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23(5):465\u2013476. https:\/\/doi.org\/10.1016\/S1474-4422(24)00052-8","journal-title":"Lancet Neurol"},{"issue":"Pt 5","key":"3205_CR12","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ (1991) Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283\u20132301","journal-title":"Brain"},{"issue":"5","key":"3205_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaneurol.2026.0577","volume":"83","author":"HH Fernandez","year":"2026","unstructured":"Fernandez HH, Isaacson SH, Hauser RA et al (2026) Tavapadon as adjunctive treatment for parkinson disease. The TEMPO-3 randomized clinical trial. JAMA Neurol 83(5):442\u2013451. https:\/\/doi.org\/10.1001\/jamaneurol.2026.0577","journal-title":"JAMA Neurol"},{"issue":"2","key":"3205_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF et al (2016) Opoicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(15)00336-1","journal-title":"Lancet Neurol"},{"issue":"10","key":"3205_CR15","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1007\/s10072-021-05550-2","volume":"42","author":"A Goel","year":"2021","unstructured":"Goel A, Sugumaran R, Narayan S (2021) Zonisamide in Parkinson\u2019s disease: a current update. Neurol Sci 42(10):4123\u20134129. https:\/\/doi.org\/10.1007\/s10072-021-05550-2","journal-title":"Neurol Sci"},{"key":"3205_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.parkreldis.2020.12002","volume":"82","author":"RA Hauser","year":"2021","unstructured":"Hauser RA, Zeitlin L, Fisher S, D\u2019Souza R (2021) Duration of benefit per dose: carbidopa-levodopa immediate release vs. extended release capsules (Rytary). Parkinsonism Relat Disord 82:133\u2013137. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12002","journal-title":"Parkinsonism Relat Disord"},{"key":"3205_CR17","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3233\/JPD-212672","volume":"11","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Hattori N, Fernandez H et al (2022) Efficacy of istradefylline, an adenosine A2a receptor antagonist, as adjunctive therapy to levodopa in Parkinson\u2019s disease: a pooled analysis of 8 phase 2b\/3 trials. J Park Dis 11:1663\u20131675. https:\/\/doi.org\/10.3233\/JPD-212672","journal-title":"J Park Dis"},{"issue":"1","key":"3205_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"G Hoeglinger","year":"2024","unstructured":"Hoeglinger G, Trenkwalder C (2024) Diagnosis and treatment of Parkinson\u2019s disease (guideline of the German Society for Neurology). Neurol Res Pract 6(1):30. https:\/\/doi.org\/10.1186\/s42466-024-00325-4","journal-title":"Neurol Res Pract"},{"key":"3205_CR19","doi-asserted-by":"publisher","first-page":"1061101","DOI":"10.1016\/j.parkreldis.2024.106101","volume":"122","author":"J Horsager","year":"2024","unstructured":"Horsager J, Borghammer P (2024) Brain-first vs. body-first Parkinson\u2019s disease: an update on recent evidence. Parkinsonism Relat Disord 122:1061101. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106101","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"3205_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1877718X241310727","volume":"15","author":"SH Isaacson","year":"2025","unstructured":"Isaacson SH, Espay AJ, Pahwa R et al (2025) Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: results from the phase 3, long-term, open-label Unites States InfusOn study. J Parkinsons Dis 15(2):361\u2013373. https:\/\/doi.org\/10.1177\/1877718X241310727","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"3205_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5603\/pjnns.103168","volume":"59","author":"J Kasprzak","year":"2025","unstructured":"Kasprzak J, Dulski J, Przytula F et al (2025) Levodopa and dopamine agonist phobia in Parkinson\u2019s disease-does it really matter? A survey on treatment patterns in polish tertiary centres. Neurol Neurochir Pol 59(1):62\u201369. https:\/\/doi.org\/10.5603\/pjnns.103168","journal-title":"Neurol Neurochir Pl"},{"key":"3205_CR22","doi-asserted-by":"crossref","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A (2003) Anti-cholinergics for symptomatic management of Parkinson\u2019s disease. Cochrane Database Syst Rev 2002(2):CD003735","DOI":"10.1002\/14651858.CD003735"},{"issue":"11","key":"3205_CR23","doi-asserted-by":"publisher","first-page":"a041945","DOI":"10.1101\/cshperspect.a041611","volume":"15","author":"S Kayhanian","year":"2025","unstructured":"Kayhanian S, Barker RA (2025) Dopamine cell-based replacement therapies. Cold Spring Harb Perspect Med 15(11):a041945. https:\/\/doi.org\/10.1101\/cshperspect.a041611","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3205_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/healthcare13101207","volume":"13","author":"BJ Kim","year":"2025","unstructured":"Kim BJ, Kim H, Lee YS et al (2025) Trends of Korean medicine treatment for Parkinson\u2019s disease in South Korea: a cross-sectional analysis using the health insurance review and assessment service-national patient sample database. Healthcare 13:1207. https:\/\/doi.org\/10.3390\/healthcare13101207","journal-title":"Healthcare"},{"key":"3205_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00415-025-12894-8","volume":"272","author":"W Kou","year":"2025","unstructured":"Kou W, Cai H, Cui Y et al (2025) Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol 272:176. https:\/\/doi.org\/10.1007\/s00415-025-12894-8","journal-title":"J Neurol"},{"key":"3205_CR27","doi-asserted-by":"publisher","unstructured":"Lees AJ, Ferreira J, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197\u2013206. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4703","DOI":"10.1001\/jamaneurol.2016.4703"},{"issue":"1\u20132","key":"3205_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","volume":"248","author":"MR Lemke","year":"2006","unstructured":"Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson\u2019s disease. J Neurol Sci 248(1\u20132):266\u2013270. https:\/\/doi.org\/10.1016\/j.jns.2006.05.024","journal-title":"J Neurol Sci"},{"issue":"2","key":"3205_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hause RA, Pahwa R, Isaacson SH et al (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18(2):145\u2013154. https:\/\/doi.org\/10.1016\/S1474-4422(18)30405-8","journal-title":"Lancet Neurol"},{"key":"3205_CR29","unstructured":"Lewy FH (1912) Paralysis agitans. In: Lewandowsky M (ed) Pathologische anatomie. Handbuch der Neurologie, vol. 3. Springer, Berlin, p 920\u2013933"},{"issue":"9","key":"3205_CR30","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40262-017-0511-y","volume":"56","author":"A Mittur","year":"2017","unstructured":"Mittur A, Gupta S, Modi NB (2017) Pharmacokinetics of Rytary\u00ae, an extended-release capsule formulation of carbidopa-levodopa. Clin Pharmacokinet 56(9):999\u20131014. https:\/\/doi.org\/10.1007\/s40262-017-0511-y","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3205_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1460-9568.1994.tb00584.x","volume":"6","author":"JA Obeso","year":"1994","unstructured":"Obeso JA, Grandas F, Herrero MT, Horowski R (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson\u2019s disease. Eur J Neurosci 6(6):889\u2013897. https:\/\/doi.org\/10.1111\/j.1460-9568.1994.tb00584.x","journal-title":"Eur J Neurosci"},{"issue":"10 Suppl","key":"3205_CR32","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/s1471-1931(00)00030-8","volume":"23","author":"CW Olanow","year":"2000","unstructured":"Olanow CW, Schapira AH, Rascol O (2000) Continuous dopamine-receptor stimulation in early Parkinson\u2019s disease. Trends Neurosci 23(10 Suppl):S117\u2013S126. https:\/\/doi.org\/10.1016\/s1471-1931(00)00030-8","journal-title":"Trends Neurosci"},{"issue":"2","key":"3205_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"3205_CR34","unstructured":"Ordenstein L (1867) Sur la paralysie agitante et la scl\u00e9rose en plaque generalis\u00e9e. Martinet, Paris"},{"key":"3205_CR35","doi-asserted-by":"publisher","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J et al (224) Prasinezumab slows motor progression in rapidly prograssing early-stage Parkinson\u2019s disease. Nat Med 30(4):1096\u20131103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y","DOI":"10.1038\/s41591-024-02886-y"},{"issue":"5","key":"3205_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jamaneurol.2026.0590","volume":"83","author":"R Pahwa","year":"2026","unstructured":"Pahwa R, Moro E, Espay A et al (2026) Fixed-dose tavapadon for early parkinson disease: a randomized clinical trial. JAMA Neurol 83(5):452\u2013460. https:\/\/doi.org\/10.1001\/jamaneurol.2026.0590","journal-title":"JAMA Neurol"},{"issue":"2","key":"3205_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneurol.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241\u2013248. https:\/\/doi.org\/10.1001\/archneurol.62.2.241","journal-title":"Arch Neurol"},{"key":"3205_CR38","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Levadan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in Parkinson\u2019s disease. Science 276:2045\u20132047","journal-title":"Science"},{"issue":"12","key":"3205_CR39","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Dosord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Dosord"},{"issue":"Suppl 1","key":"3205_CR40","first-page":"105","volume":"27","author":"NP Quinn","year":"1987","unstructured":"Quinn NP, Mariion MH, Marsden CD (1987) Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson\u2019s disease and on-off fluctuations. Eur Neurol 27(Suppl 1):105\u2013113","journal-title":"Eur Neurol"},{"issue":"2","key":"3205_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archneur58.2.249","volume":"58","author":"O Rascol","year":"2001","unstructured":"Rascol O, Nutt JG, Goetz CG et al (2001) Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol 58(2):249\u2013254. https:\/\/doi.org\/10.1001\/archneur58.2.249","journal-title":"Arch Neurol"},{"issue":"9463","key":"3205_CR42","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effecxt in Adjunct therapy with Rasagiline Given Once daily study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947\u2013954. https:\/\/doi.org\/10.1016\/S0140-6736(05)71083-7","journal-title":"Lancet"},{"issue":"5","key":"3205_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000523771","volume":"85","author":"H Reichmann","year":"2022","unstructured":"Reichmann H, Eggert K, Oehlwein C et al (2022) Opicapone use in clinical practice across Germany: a sub-analysis of the OPTIPARK study in Parkinson\u2019s disease patients with motor fluctuations. Eur Neurol 85(5):389\u2013397. https:\/\/doi.org\/10.1159\/000523771","journal-title":"Eur Neurol"},{"issue":"5","key":"3205_CR44","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1212\/wnl.51.5.1309.","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt study group. Neurology 51(5):1309\u20131314. https:\/\/doi.org\/10.1212\/wnl.51.5.1309","journal-title":"Neurology"},{"issue":"804","key":"3205_CR45","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto N, Doi D, Nakanishi E et al (2025) PhaseI\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature 641(804):971\u2013977. https:\/\/doi.org\/10.1038\/s41586-025-08700-0","journal-title":"Nature"},{"key":"3205_CR46","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/jama.1969.03160070046011","volume":"208","author":"RS Schwab","year":"1969","unstructured":"Schwab RS, England AC Jr, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson\u2019s disease. J Am Med Assoc 208:1163\u20131170","journal-title":"J Am Med Assoc"},{"issue":"2","key":"3205_CR47","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov Disord 32(2):283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov Disord"},{"issue":"12","key":"3205_CR48","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-forcarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled phase 3 trial. Lancet Neurol 21(12):1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"issue":"6645","key":"3205_CR49","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"28","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nat 28(6645):839\u2013840. https:\/\/doi.org\/10.1038\/42166","journal-title":"Nat Aug"},{"issue":"3","key":"3205_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00002826-1991106000-00007","volume":"14","author":"MJ Steiger","year":"1991","unstructured":"Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD (1991) The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon \u201coff\u201d periods in Parkinson\u2019s disease. Clin Neuropharmacol 14(3):241\u2013244. https:\/\/doi.org\/10.1097\/00002826-1991106000-00007","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"3205_CR51","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800\u2013809. https:\/\/doi.org\/10.1212\/WNL.0b013e318285c0ed","journal-title":"Neurology"},{"key":"3205_CR52","volume-title":"Contribution \u00e0 l\u2019\u00e9tude des l\u2019anatomie pathologique due locus nigre de Soemmering avex quelques d\u00e9ductions relatives \u00e0 la pathologie des troubles musculaires et de la maladie de Parkinson","author":"C Tretiakoff","year":"1919","unstructured":"Tretiakoff C (1919) Contribution \u00e0 l\u2019\u00e9tude des l\u2019anatomie pathologique due locus nigre de Soemmering avex quelques d\u00e9ductions relatives \u00e0 la pathologie des troubles musculaires et de la maladie de Parkinson. Jouve, Paris"},{"key":"3205_CR53","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.2174\/15701159X21666230731110709","volume":"22","author":"DJ Van Wamelen","year":"2024","unstructured":"Van Wamelen DJ, Leta V, Chaushuri KR, Jenner P (2024) Future directions for developing non-dopaminergic strategies for the treatment of Parkinson\u2019s disease. Curr Neuropharm 22:1606\u20131620. https:\/\/doi.org\/10.2174\/15701159X21666230731110709","journal-title":"Curr Neuropharm"},{"key":"3205_CR54","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/wnl.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P et al (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50:1323\u20131326. https:\/\/doi.org\/10.1212\/wnl.50.5.1323","journal-title":"Neurology"},{"issue":"7","key":"3205_CR55","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.22890","volume":"25","author":"RL Watts","year":"2010","unstructured":"Watts RL, Lyons KE, Pahwa R et al (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson\u2019s disease. Mov Disord 25(7):858\u2013866. https:\/\/doi.org\/10.1002\/mds.22890","journal-title":"Mov Disord"},{"key":"3205_CR56","doi-asserted-by":"publisher","first-page":"120087","DOI":"10.1016\/j.JAD.2025.120087","volume":"392","author":"X Wei","year":"2026","unstructured":"Wei X, Xu F, Zhang X et al (2026) Efficacy and tolerability of pramipexole versus antidepressants for Parkinson\u2019s disease with depression: a meta-analysis of randomized controlled trials. J A\u00e4ffect Disord 392:120087. https:\/\/doi.org\/10.1016\/j.JAD.2025.120087","journal-title":"J A\u00e4ffect Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03205-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:52:19Z","timestamp":1781790739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03205-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":56,"alternative-id":["3205"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03205-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}